l.parkinson
TL2 Member · Lublin, PL
Practical questions, practical answers. Not interested in speculation without a source.
Joined 12 January 2025 · last posted 6h
95Posts here
0Topics
0Solutions
535Likes received
441Likes given
20Badges
154Days visited
1.6kPosts read
Recent activity
Full stream-
Sulfonylureas: the interaction most worth taking seriously Replied, post #9 · Practice › Interactions · 28 Jul 2026 · 21 likes A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper interaction database, and that access is the thing a forum does not…
-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #32 · Lounge › Off topic · 23 Jul 2026 · 0 likes Lounge-level thought to close on: the measure of this place is that being wrong in public here is cheap. That is a design decision and it took work. I would be…
-
What is genuinely unknown about long-term amylin agonism Replied, post #54 · Compounds › Cagrilintide & amylin analogues · 18 Jul 2026 · 11 likes What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs…
-
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #109 · Evidence › Journal club · 15 Jul 2026 · 19 likes I would put moderate confidence on the mainstream reading of SURMOUNT-OSA and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #119 · Evidence › Journal club · 13 Jul 2026 · 9 likes Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #52 · Practice › Dosing & titration · 10 Jul 2026 · 18 likes Taking post #50 at face value and following it one step further. The most common practical error is not the schedule at all — it is losing track of which step you are…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #30 · Compounds › Secretagogues & GH axis · 9 Jul 2026 · 23 likes Building on post #27 rather than restating it. Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #60 · Analytics › Impurities & related substances · 9 Jul 2026 · 5 likes Trifluoroacetate is a counter-ion rather than an impurity, and it appears in the mass balance rather than in the chromatogram. Conflating the two accounts for several…
-
A critique that turned out to be unfair, retracted by its author Replied, post #26 · Evidence › Study critique · 8 Jul 2026 · 20 likes I had written a reply contradicting post #24 and deleted it. Here is what survived. Generalisability and validity are separate axes. A trial can be internally…
-
Tracking a shortage from primary sources rather than rumour Replied, post #78 · Access › Shortages · 1 Jul 2026 · 0 likes Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
-
Journal club: what we got wrong in an earlier session Replied, post #22 · Evidence › Journal club · 23 Jun 2026 · 15 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later. It is one…
-
Follow-up: Reading an interaction checker output critically Replied, post #13 · Practice › Interactions · 21 Jun 2026 · 3 likes Taking post #12 at face value and following it one step further. Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the…